NCT07486037 Caring for Caregivers of Individuals With Alzheimer's Disease
| NCT ID | NCT07486037 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Indiana University |
| Condition | Intervention Group |
| Study Type | INTERVENTIONAL |
| Enrollment | 25 participants |
| Start Date | 2026-03-01 |
| Primary Completion | 2028-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 25 participants in total. It began in 2026-03-01 with a primary completion date of 2028-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
What is this study about? This study is called the EMBRACE Study - A Virtual Community Empowerment Approach Integrating Tradition and Technology for Family Caregivers of Individuals with Alzheimer's Disease. It tests whether a home-based virtual exercise program can reduce depression and anxiety in family caregivers of people living with Alzheimer's disease and related dementias (ADRD). Why is this study needed? Caring for a loved one with ADRD is demanding and is strongly linked to depression and anxiety. Regular exercise is one of the most effective ways to reduce these symptoms - but caregivers often cannot leave home to exercise due to the needs of their loved one, transportation concerns, and safety issues. What does participation involve? Participants will be randomly assigned (like a coin flip) to one of two groups: * EMBRACE group: 24 weekly virtual group exercise sessions over 3 months (about 1 hour each), using an at-home elliptical device provided by the study. Months 4-6 include weekly check-in calls to support independent exercise. Educational sessions on habit-building and goal-setting are included. * Wait-list control group: Completes the same surveys and measurements; receives the program after data collection ends. Who can join? Adults (18+) who are the primary unpaid caregiver for someone with ADRD, can read and speak English, and are healthy enough to exercise. Participants do not need to leave home - everything is virtual. What is being measured? Exercise time (using a wearable device), symptoms of depression and anxiety, and whether the program is feasible and acceptable to participants. Where is the study based? Indiana University Indianapolis. The study is conducted entirely virtually and remotely.
Eligibility Criteria
Inclusion Criteria: * Self-identifies as African American * Age 18 years or older * Primary unpaid caregiver for an adult living with Alzheimer's disease or a related dementia (ADRD) * Able to read and speak English * Deemed sufficiently healthy to participate in exercise per the PAR-Q+ screening questionnaire * Has access to an email address Exclusion Criteria: * Diagnosed psychiatric illness * Untreated severe major depression * Currently receiving advanced cancer treatment or hospice care * Currently receiving dialysis * Severe hearing loss without hearing aids * Severe vision impairment without corrective eyeglasses * No access to a phone or email * Unable to safely exercise based on PAR-Q+ screening * Already meeting the recommended physical activity guidelines at the time of enrollment
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07486037 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Intervention Group. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07486037 currently recruiting?
Yes, NCT07486037 is actively recruiting participants. Contact the research team at nkaushal@iu.edu for enrollment information.
Where is the NCT07486037 trial being conducted?
This trial is being conducted at Indianapolis, United States.
Who is sponsoring the NCT07486037 clinical trial?
NCT07486037 is sponsored by Indiana University. The trial plans to enroll 25 participants.